Topic: multiple sclerosis
Mayzent was the first multiple sclerosis drug to be cleared in the secondary progressive form of the disease in more than 15 years.
A Brigham and Women's team found a microRNA in the microbiome that increases when MS peaks. Giving it back to mice as a treatment relieved symptoms.
Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.
Newly identified gene variants that play a role in MS-related vision loss could help guide precision medicine and drug development, researchers say.
Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.
Troubled Big Biotech Biogen is losing its head of research and development Michael Ehlers, M.D., Ph.D., as its chief medical officer takes over the role.
In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.
The study tested a 20 mg dose of ponesimod against a 14 mg dose of Aubagio in adults with relapsing multiple sclerosis over a period of two years.
A revised flavonoid could promote the regrowth of functional myelin in mice, scientists at the Oregon Health & Science University have shown.
Stanford researchers discovered that immune cells known for their ability to root out cancer can also kill wayward cells that cause MS.